Valeant Pharmaceuticals International Target of Unusually High Options Trading (NYSE:VRX) – The Cerbat Gem

This article was originally published on this site

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) (TSE:VRX) saw some unusual options trading on Friday. Stock traders purchased 35,088 put options on the company. This represents an increase of 215% compared to the typical daily volume of 11,124 put options.

Valeant Pharmaceuticals International (NYSE VRX) opened at 17.30 on Friday. The stock has a 50 day moving average price of $13.59 and a 200-day moving average price of $12.98. Valeant Pharmaceuticals International has a 1-year low of $8.31 and a 1-year high of $32.74. The stock’s market capitalization is $6.02 billion.

Valeant Pharmaceuticals International (NYSE:VRX) (TSE:VRX) last posted its quarterly earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported $2.80 EPS for the quarter, beating the consensus estimate of $0.87 by $1.93. Valeant Pharmaceuticals International had a negative net margin of 14.96% and a positive return on equity of 58.02%. The company had revenue of $2.11 billion for the quarter, compared to analyst estimates of $2.17 billion. During the same period in the prior year, the company earned ($1.08) earnings per share. The firm’s revenue was down 11.1% on a year-over-year basis. Equities research analysts expect that Valeant Pharmaceuticals International will post $3.89 EPS for the current year.

A number of brokerages have weighed in on VRX. Jefferies Group LLC set a $18.00 target price on Valeant Pharmaceuticals International and gave the stock a “buy” rating in a research note on Saturday, May 6th. Guggenheim began coverage on Valeant Pharmaceuticals International in a research note on Saturday, June 17th. They issued a “buy” rating and a $18.00 target price on the stock. Mizuho reiterated an “underperform” rating and issued a $8.00 price objective on shares of Valeant Pharmaceuticals International in a report on Tuesday, June 20th. Stifel Nicolaus reiterated a “buy” rating and issued a $35.00 price objective on shares of Valeant Pharmaceuticals International in a report on Friday. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a $19.00 price objective (up from $18.00) on shares of Valeant Pharmaceuticals International in a report on Wednesday, May 10th. Two equities research analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $16.51.

In related news, Director Schutter Richard U. De acquired 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 11th. The shares were bought at an average cost of $13.90 per share, for a total transaction of $278,000.00. Following the purchase, the director now owns 70,572 shares in the company, valued at approximately $980,950.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 5.87% of the company’s stock.

A number of large investors have recently bought and sold shares of the stock. GSA Capital Partners LLP raised its stake in Valeant Pharmaceuticals International by 32.7% in the fourth quarter. GSA Capital Partners LLP now owns 35,415 shares of the specialty pharmaceutical company’s stock valued at $514,000 after buying an additional 8,718 shares during the last quarter. A.R.T. Advisors LLC acquired a new stake in Valeant Pharmaceuticals International during the fourth quarter valued at approximately $1,196,000. Public Sector Pension Investment Board raised its stake in Valeant Pharmaceuticals International by 3.1% in the fourth quarter. Public Sector Pension Investment Board now owns 522,217 shares of the specialty pharmaceutical company’s stock valued at $7,582,000 after buying an additional 15,900 shares during the last quarter. Renaissance Technologies LLC raised its stake in Valeant Pharmaceuticals International by 573.6% in the fourth quarter. Renaissance Technologies LLC now owns 2,913,089 shares of the specialty pharmaceutical company’s stock valued at $42,294,000 after buying an additional 2,480,600 shares during the last quarter. Finally, Credit Agricole S A raised its stake in Valeant Pharmaceuticals International by 27.4% in the fourth quarter. Credit Agricole S A now owns 56,822 shares of the specialty pharmaceutical company’s stock valued at $825,000 after buying an additional 12,236 shares during the last quarter. 50.45% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Valeant Pharmaceuticals International Target of Unusually High Options Trading (NYSE:VRX)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2017/07/01/traders-buy-large-volume-of-valeant-pharmaceuticals-international-put-options-vrx-updated.html.

Valeant Pharmaceuticals International Company Profile

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

Receive News & Stock Ratings for Valeant Pharmaceuticals International Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Valeant Pharmaceuticals International Inc. and related stocks with our FREE daily email newsletter.